Analysis of Safety Signals in Multiple Sclerosis Disease-Modifying Therapies (Human Subjects)
A study analyzed adverse drug events (ADEs) linked to multiple sclerosis disease-modifying therapies (DMTs), finding high rates of systemic symptoms, infections, liver injury, and alopecia. It flagged progressive multifocal leukoencephalopathy (PML) and spontaneous abortion as severe risks, particularly with anti-CD20 therapies and natalizumab, respectively. Most adverse events occurred within 2 years of treatment initiation.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
This analysis highlights specific safety concerns related to MS DMTs, emphasizing the need for clinical vigilance and potential further investigation into these risks, especially considering the impact on patient health.
What this does not prove
The study provides only hypothesis-generating evidence without estimating incidence, comparative risk, or causality, limiting its ability to provide definitive conclusions about the risks associated with these therapies.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- No
- Controlled
- No
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-13
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- anti-CD20 antibodies, natalizumab, teriflunomide
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Progressive multifocal leukoencephalopathy (PML) identified as high-risk severe event.; Spontaneous abortion identified as high-risk severe event.; The study identifies drug-specific safety signatures.
Original sources
- Primary evidenceFifteen-year real-world pharmacovigilance of multiple sclerosis disease-modifying therapies: adverse event profiles, drug-specific safety signals and clinical implications. ↗DOI: 10.3389/fneur.2026.1845881
Supporting passages (11)
sample size basisADE reports
randomizedNo
controlledNo
publication date2026-10-13
interventionmultiple sclerosis disease-modifying therapies
findingsThe most common ADEs were systemic symptoms, infections, liver injury and alopecia.
limitationsCONCLUSIONS: This long-term FAERS-based analysis identified potential safety signals associated with major MS DMTs, providing hypothesis-generating evidence to support clinical vigilance and prioritize further validation, but not to estimate incidence, comparative risk, or causality.
biological targetsDrug-specific analysis revealed distinct safety signatures: anti-CD20 antibodies carried the highest infection risk, natalizumab was strongly associated with PML (ROR = 45.62), and teriflunomide had the highest alopecia risk (ROR = 12.73).
safety signalsNotably, progressive multifocal leukoencephalopathy (PML, ROR = 15.59) and spontaneous abortion (ROR = 2.54) were identified as high-risk severe events.
peer reviewedPublication types: Journal Article
subjectsTime-to-onset (TTO) analysis with Weibull distribution and multivariate logistic regression were performed to assess temporal risk patterns and patient-specific risk factors for important medical events (IMEs).
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.